Drug regulators say they have received reports of stomach paralysis among patients taking GLP-1 agonist drugs.

“The FDA has received reports of gastroparesis with semaglutide and liraglutide, some of which documented the adverse event as not recovered after discontinuation of the respective product at the time of the report,” the agency said in a statement to CNN.

The reports have been submitted through the agency’s publicly accessible adverse events tracking system, and the agency said there’s not always enough information in those reports to properly evaluate them.

The FDA said it has been unable to determine if the medications were the cause or if the gastroparesis may have been caused by a different issue.

Read more at CNN >>

To read more about the aesthetic history, legal concerns and latest coverage on semaglutide, visit AmSpa’s Medical Aesthetic Semaglutide Resource Center at https://americanmedspa.org/med-spa-semaglutides.